Results 81 to 90 of about 254,031 (357)

Real World Effectiveness and Tolerability of Novel Monoclonal Antibodies and Rituximab for NMOSD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT In this multicenter retrospective cohort study of 135 people with aquaporin‐4 IgG+ neuromyelitis optica spectrum disorder (NMOSD), some of whom were exposed to multiple therapies, we evaluated the effectiveness and tolerability of rituximab (n = 111) and novel monoclonal antibodies (nMAbs): eculizumab (n = 9), inebilizumab (n = 23), and ...
Zarmina Javed, Mengke Du, Mary Rensel, Le H. Hua, Carrie M. Hersh, Justin R. Abbatemarco, Devon S. Conway, Daniel Ontaneda, Jeffrey A. Cohen, Amy Kunchok   +9 more
wiley   +1 more source

Durability of Response to B‐Cell Maturation Antigen‐Directed mRNA Cell Therapy in Myasthenia Gravis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective We report the 12‐month follow‐up outcomes from a Phase 2 clinical trial (NCT04146051) evaluating Descartes‐08, a BCMA‐directed RNA chimeric antigen receptor T‐cell (rCAR‐T) therapy for refractory generalized myasthenia gravis (MG).
Nizar Chahin, Gregory Sahagian, Marc H. Feinberg, C. Andrew Stewart, Christopher M. Jewell, Metin Kurtoglu, Miloš D. Miljković, Tuan Vu, Tahseen Mozaffar, James F. Howard Jr, the MG‐001 Study Group   +10 more
wiley   +1 more source

Immunosuppressive drugs and major complications in pediatric renal transplantation

Iatreia, 2017
Pediatric renal transplantation is the treatment of choice in children with chronic kidney disease. Many agents are available for immunosuppressive therapy, which are used in two different regimes: first for the induction phase, and then for maintenance.
Guerrero-Tinoco, Gustavo Adolfo, Villafañe-Bermúdez, Douglas Ramón, Vélez-Echeverri, Catalina   +2 more
doaj   +1 more source

Irradiation to Improve the Response to Immunotherapeutic Agents in Glioblastomas. [PDF]

, 2019
PurposeGlioblastoma (GBM) remains an incurable disease despite extensive treatment with surgical resection, irradiation, and temozolomide. In line with many other forms of aggressive cancers, GBM is currently under consideration as a target for ...
Kaprealian, Tania, Lee, Mi-Heon, McBride, William H, Nesseler, Jean Philippe, Nickers, Philippe, Niclou, Simone P, Schaue, Dorthe   +6 more
core  

Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity. [PDF]

, 2018
Regulatory T cells (Tregs) are critical for maintaining immune homeostasis, but their presence in tumor tissues impairs anti-tumor immunity and portends poor prognoses in cancer patients.
Abnousian, Arbi, Bluestone, Jeffrey A, DuPage, Michel, Fong, Lawrence, Harwin, Tory, Mahuron, Kelly, Pagani, Massimiliano, Pai, Chien-Chun, Quiros, Jason, Ranzani, Valeria, Rosenblum, Michael D, Silveria, Stephanie, Van Gool, Frederic, Wang, David, Young, Arabella   +14 more
core   +2 more sources

Recommendations for the Use of Disease‐Modifying Antirheumatic Drugs in Pregnancy and Reproductive Health for Patients With Rheumatic Disease: A Scoping Review

Arthritis Care &Research, EarlyView.
Objective Autoimmune rheumatic diseases commonly affect individuals of childbearing age, with historically increased adverse pregnancy outcomes in this group. The advent of disease‐modifying antirheumatic drugs (DMARDs) has fostered more suitable conditions for pregnancy; however, this is accompanied by challenges in ensuring safe use in reproductive ...
Athena Chin, Alice Terrett, Mihye Kwon, Samuel Whittle, Catherine Hill   +4 more
wiley   +1 more source

Acute psychotic disorder associated with immunosuppressive agent use after renal transplantation: a case report

Psychiatry and Clinical Psychopharmacology, 2017
Kidney transplantation is the best treatment option for end-stage renal disease in appropriate patients. Immunosuppressant agents given in this duration can cause many psychiatric disorders.
Fulya Gok, Meliha Zengin Eroglu
doaj   +1 more source

Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis : Fundamentals Of Care for UveitiS (FOCUS) Initiative [PDF]

, 2018
Supplemental material available at www.aaojournal.org. Supported by AbbVie, Inc., and the Fundamentals of Care for Uveitis Initiative National Faculty.
Accorinti, Massimo, Acharya, Nisha, Adan, Alfredo, Agrawal, Rupesh, Akkoc, Nurullah, Al Ghamdi, Saed, Al Ghamdi, Turki, Al Saati, Anood, Al-Dhibi, Hassan A., Al-Shamarani, Mohamed, Alsabaani, Nasser, Bachta, Artur, Barisani-Asenbauer, Talin, Beare, Nicholas, Belfort, Rubens, Blanco, Ricardo, Brézin, Antoine P., Carreño, Ester, Chandran, Vinod, Chee, Soon Phaik, Chiquet, Christophe, Chng, Hiok Hee, Cimbalas, Andrius, Cimino, Luca, Cordero-Coma, Miguel, Cristobal, Couto, Cuevas, Miguel, Davis, Janet L., de Boer, Joke, de la Torre, Alejandra, De Schryver, Ilse, Derzko-Dzulynsky, Larissa, Diaz-Valle, David, Dick, Andrew D., Eurico da Fonseca, João, Facsko, Andrea, Figueira, Luis, Fundamentals of Care for Uveitis International Consensus Group, Kuffova, Lucia, Merino, Claudia Eugenia Duran, Murphy, Conor, Nascimento, Heloisa, Porto, Fernanda Belga Ottoni, Ramanan, Athimalaipet V., Rosenbaum, James T., Salah, Sawsen, Salek, Sherveen, Siak, Jay, Sonoda, Koh Hei, Steeples, Laura, Yee, Anita Chan Sook   +50 more
core   +1 more source

Treating lupus nephritis patients to lupus low disease activity reduces renal relapse and preserves long‐term kidney function

Arthritis Care &Research, Accepted Article.
Objective Lupus low disease activity state (LLDAS) is a validated treatment target in systemic lupus erythematosus (SLE) but limited studies have explored the role of LLDAS in lupus nephritis (LN). This study aims to investigate the frequency and predictors of LLDAS attainment, and its benefit on LN relapse and renal function preservation in patients ...
Chak Kwan Cheung, Desmond YH Yap, KL Lee, Philip H Li, Iris YK Tang, Chak Sing Lau, Shirley CW Chan   +6 more
wiley   +1 more source

Inhibition of Glutamine Metabolism Attenuates Tumor Progression Through Remodeling of the Macrophage Immune Microenvironment

Advanced Biology, EarlyView.
The prodrug strategy used in this study offers new promise for cancer metabolism‐based therapies. JHU083, a prodrug that, when cleaved by protease in the tumor microenvironment, yields the glutamine antagonist DON. JHU083 inhibits tumor growth by targeting glutamine‐addicted cancer cells and suppressing glutamine‐dependent M2 macrophages, leading to a ...
Tianhe Li, Sepehr Akhtarkhavari, Sumeng Qi, Jiawei Fan, Tu‐Yung Chang, Yao‐An Shen, JinMing Yang, Barbara S. Slusher, Ie‐Ming Shih, Stephanie Gaillard, Tian‐Li Wang   +10 more
wiley   +1 more source